Use of Antifungal Combination Therapy: Agents, Order, and Timing.
about
The hyperimmunoglobulin E syndrome--clinical manifestation diversity in primary immune deficiencyPosaconazole exhibits in vitro and in vivo synergistic antifungal activity with caspofungin or FK506 against Candida albicansCross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazoleAmino acid substitutions at the major insertion loop of Candida albicans sterol 14alpha-demethylase are involved in fluconazole resistance.The challenge of managing fusariosisOutcome of Antifungal Combination Therapy for Invasive Mold Infections in Hematological Patients is Independent of the Chosen Combination.Clinical management of infectious cerebral vasculitides.Pharmacodynamics of anidulafungin against clinical Aspergillus fumigatus isolates in a nonneutropenic murine model of disseminated aspergillosis.Induction of Protective Immunity to Cryptococcal Infection in Mice by a Heat-Killed, Chitosan-Deficient Strain of Cryptococcus neoformans.Impact of in vivo triazole and echinocandin combination therapy for invasive pulmonary aspergillosis: enhanced efficacy against Cyp51 mutant isolatesAddressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations.Voriconazole in clinical practice.Combination antifungal therapy for invasive fungal infections in children and adults.Azole antifungals: 35 years of invasive fungal infection management.The amino acid substitution N136Y in Candida albicans sterol 14alpha-demethylase is involved in fluconazole resistance.New pharmacological opportunities for the treatment of invasive mould diseases.Curcumin enhances the activity of fluconazole against Cryptococcus gattii-induced cryptococcosis infection in mice.Honokiol induces superoxide production by targeting mitochondrial respiratory chain complex I in Candida albicansCotrimoxazole enhances the in vitro susceptibility of Coccidioides posadasii to antifungals.Current role of echinocandins in the management of invasive aspergillosis.Synergistic activity of magnolol with azoles and its possible antifungal mechanism against Candida albicans.Review on fungal enzyme inhibitors – potential drug targets to manage human fungal infections
P2860
Q21202861-CB378280-EECA-46C7-B220-3A7B97716236Q28487653-F605D6D5-1B00-4CE4-AE8D-FE25837B1399Q33939052-724E9A3B-8ACA-4D87-AE91-7D70C79DB300Q33940714-F9F9655B-5AD8-4F29-A00F-00F7243DC008Q35693680-773E6031-48A8-4B7F-B272-3DACE6C13E2CQ35756513-58D2C25F-7484-4733-9D3E-018A3FFD3774Q35874045-DDD55CCF-A6DC-44D7-BCB1-9ADB393744C6Q36505281-40A2EB7D-F88D-4D0C-A2C7-529E950CB95AQ37123421-09DBEBAD-B7CD-4EC4-9C37-7D0F50EAD1F9Q37263430-4CED5B51-09DF-4830-858C-7C033591961BQ37918556-AEF5CDE8-4A83-42FC-AA5D-A00FD4305F18Q38061736-AC1C2735-12EE-43B6-9072-9A329DA2A235Q38102782-BDF1B5E9-34EF-4CB6-A696-D977F20EA60EQ38406393-F2DF149F-AA33-44DC-BBCE-A5C94DA35417Q39796596-E1D166D2-DC4F-4E01-BB42-B2145B11618BQ40273481-C4C6D440-5265-4266-B93B-4BCB7D019806Q40963460-E9C1337B-4995-4AA1-9C4D-69897F55FBD5Q41561738-20125D8C-5D0C-4410-AF9B-E916713809A8Q50976143-429D743B-EC10-4455-AC1B-754AD5E1869DQ53217028-7A86932E-3533-4BF4-AF26-395F9B43C6DBQ53622505-62212286-4C68-4C94-8271-784590EDB43AQ57705350-EBD55BF2-CF24-4857-91AE-03B64A7FD1DB
P2860
Use of Antifungal Combination Therapy: Agents, Order, and Timing.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Use of Antifungal Combination Therapy: Agents, Order, and Timing.
@en
Use of Antifungal Combination Therapy: Agents, Order, and Timing.
@nl
type
label
Use of Antifungal Combination Therapy: Agents, Order, and Timing.
@en
Use of Antifungal Combination Therapy: Agents, Order, and Timing.
@nl
prefLabel
Use of Antifungal Combination Therapy: Agents, Order, and Timing.
@en
Use of Antifungal Combination Therapy: Agents, Order, and Timing.
@nl
P2860
P1476
Use of Antifungal Combination Therapy: Agents, Order, and Timing.
@en
P2093
Melissa D Johnson
P2860
P2888
P356
10.1007/S12281-010-0018-6
P577
2010-05-01T00:00:00Z